Hansa Biopharma — December 2024
-
Shorting Hansa Biopharma https://shortnordic.com/details_company.php?company=hansa biopharma&land=sweden
-
Tilsyneladende en ny Hansa Biopharma hjemmeside:
Hansa Biopharma - Home
We develop lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.
(www.hansabiopharma.com)
-
FYI Hansa Biopharma
shorting: https://shortnordic.com/history_company.php?selskapsnavn=HANSA BIOPHARMA&land=sweden -
Hansa Biopharma GBS has advanced to become a value driver
(Redeye Research Note 2024-12-20 12:34)
-
Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS. This is an orphan indication, and GBS is an acute disease in patients that tends to become non-ambulatory within weeks rapidly. If approved, Imflifidase will expand into a dynamic market. We increase our base case to SEK 130 from 125 (Bull SEK 220, Bear SEK 15).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind